PECAM1 and colorectal carcinoma: The NPs-based treatment resulted in the reduction of the endothelial cell marker CD31 and consequently reduced the angiogenic potential of the CRC spheroids, demonstrating the efficiency of the CRC model in screening anti-angiogenic drugs and nanoparticles.